0001104659-24-074873.txt : 20240625 0001104659-24-074873.hdr.sgml : 20240625 20240625210408 ACCESSION NUMBER: 0001104659-24-074873 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240624 FILED AS OF DATE: 20240625 DATE AS OF CHANGE: 20240625 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: HARTOUNIAN HARTOUN CENTRAL INDEX KEY: 0001214476 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36641 FILM NUMBER: 241070404 MAIL ADDRESS: STREET 1: 4264 CORTE FAVOR CITY: SAN DIEGO STATE: CA ZIP: 92130 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: BRAINSTORM CELL THERAPEUTICS INC. CENTRAL INDEX KEY: 0001137883 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 207273918 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1325 AVENUE OF AMERICAS STREET 2: 28TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10019 BUSINESS PHONE: 201-488-0460 MAIL ADDRESS: STREET 1: 1325 AVENUE OF AMERICAS STREET 2: 28TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10019 FORMER COMPANY: FORMER CONFORMED NAME: BRAINSTORM CELL THERAPEUTICS INC DATE OF NAME CHANGE: 20041122 FORMER COMPANY: FORMER CONFORMED NAME: GOLDEN HAND RESOURCES INC DATE OF NAME CHANGE: 20030827 FORMER COMPANY: FORMER CONFORMED NAME: WIZBANG TECHNOLOGIES INC DATE OF NAME CHANGE: 20010409 4 1 tm2418256-2_4seq1.xml OWNERSHIP DOCUMENT X0508 4 2024-06-24 0 0001137883 BRAINSTORM CELL THERAPEUTICS INC. BCLI 0001214476 HARTOUNIAN HARTOUN C/O BRAINSTORM CELL THERAPEUTICS INC. 1325 AVENUE OF THE AMERICAS 28TH FLOOR NEW YORK NY 10019 0 1 0 0 EVP, Chief Operating Officer 0 Common Stock 2024-06-24 4 A 0 30000 0 A 30000 D Stock Option (Right to Buy) 0.38 2024-06-24 4 A 0 60000 0.00 A 2034-06-24 Common Stock 60000 60000 D Represents shares of restricted stock units ("RSUs") awarded under the Issuer's 2014 Stock Incentive Plan (the "Plan"). The RSUs will vest in full on June 24, 2025, provided that the Reporting Person remains employed by Issuer from the date of grant through the vesting date. The option (the "Option"), awarded under the Plan, shall vest and become exercisable as to 25% of the underlying shares on June 24, 2025, and the remaining shares underlying the Option shall vest and become exercisable in equal quarterly installments thereafter, until fully vested and exercisable on the fourth anniversary of the grant date, provided that the Reporting Person remains employed by Issuer from the date of grant through each applicable vesting date. /s/ Hartoun Hartounian 2024-06-25